Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatectomy | 12 | 2022 | 1956 | 1.050 |
Why?
|
| Transurethral Resection of Prostate | 2 | 2024 | 85 | 1.040 |
Why?
|
| Urology | 4 | 2024 | 423 | 0.970 |
Why?
|
| Prostatic Hyperplasia | 3 | 2024 | 530 | 0.900 |
Why?
|
| Urologic Surgical Procedures | 3 | 2019 | 309 | 0.820 |
Why?
|
| Lasers, Solid-State | 1 | 2024 | 175 | 0.780 |
Why?
|
| Kidney Calices | 2 | 2011 | 26 | 0.680 |
Why?
|
| Prostatic Neoplasms | 18 | 2023 | 11336 | 0.620 |
Why?
|
| Laparoscopy | 10 | 2019 | 2147 | 0.600 |
Why?
|
| Robotics | 5 | 2014 | 874 | 0.560 |
Why?
|
| Laser Therapy | 1 | 2024 | 1089 | 0.560 |
Why?
|
| Kidney Calculi | 3 | 2017 | 468 | 0.530 |
Why?
|
| Carcinoma, Transitional Cell | 4 | 2023 | 800 | 0.510 |
Why?
|
| Nephrostomy, Percutaneous | 2 | 2017 | 82 | 0.510 |
Why?
|
| Urinary Bladder Neoplasms | 6 | 2023 | 2276 | 0.450 |
Why?
|
| Nephrectomy | 7 | 2015 | 1016 | 0.440 |
Why?
|
| Penile Neoplasms | 2 | 2021 | 162 | 0.430 |
Why?
|
| Prostate | 7 | 2024 | 1791 | 0.410 |
Why?
|
| Urinary Calculi | 1 | 2011 | 91 | 0.380 |
Why?
|
| Varicocele | 1 | 2011 | 78 | 0.380 |
Why?
|
| Electrocoagulation | 1 | 2011 | 152 | 0.360 |
Why?
|
| Blood Loss, Surgical | 1 | 2014 | 653 | 0.360 |
Why?
|
| Urine | 1 | 2011 | 363 | 0.350 |
Why?
|
| Diverticulum | 1 | 2011 | 137 | 0.340 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2011 | 183 | 0.340 |
Why?
|
| Medicine | 1 | 2017 | 942 | 0.330 |
Why?
|
| Clinical Competence | 4 | 2019 | 4775 | 0.320 |
Why?
|
| Blood Transfusion | 2 | 2017 | 1321 | 0.320 |
Why?
|
| Ureter | 2 | 2012 | 375 | 0.320 |
Why?
|
| Nomograms | 1 | 2010 | 237 | 0.320 |
Why?
|
| Ablation Techniques | 1 | 2011 | 248 | 0.300 |
Why?
|
| Testis | 1 | 2011 | 794 | 0.300 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2007 | 80 | 0.290 |
Why?
|
| Computer Simulation | 2 | 2019 | 6201 | 0.270 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2011 | 621 | 0.260 |
Why?
|
| Kidney Neoplasms | 8 | 2015 | 4312 | 0.250 |
Why?
|
| Ureteral Obstruction | 1 | 2007 | 292 | 0.250 |
Why?
|
| Prostate-Specific Antigen | 7 | 2022 | 2528 | 0.250 |
Why?
|
| Internship and Residency | 5 | 2024 | 5865 | 0.250 |
Why?
|
| Endoscopy | 3 | 2024 | 1834 | 0.250 |
Why?
|
| Holmium | 1 | 2024 | 29 | 0.240 |
Why?
|
| Cryosurgery | 3 | 2015 | 475 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2015 | 9273 | 0.220 |
Why?
|
| Cystectomy | 5 | 2023 | 697 | 0.200 |
Why?
|
| Incidental Findings | 1 | 2007 | 694 | 0.200 |
Why?
|
| Urinary Bladder | 5 | 2023 | 1166 | 0.190 |
Why?
|
| Neurilemmoma | 1 | 2007 | 523 | 0.190 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2007 | 733 | 0.190 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2022 | 187 | 0.180 |
Why?
|
| Male | 47 | 2024 | 358747 | 0.160 |
Why?
|
| Treatment Outcome | 15 | 2024 | 64378 | 0.160 |
Why?
|
| Postoperative Complications | 6 | 2017 | 15637 | 0.150 |
Why?
|
| Lymphatic Metastasis | 3 | 2022 | 2943 | 0.150 |
Why?
|
| Suture Techniques | 2 | 2014 | 788 | 0.150 |
Why?
|
| Biopsy | 4 | 2023 | 6768 | 0.130 |
Why?
|
| Nephrons | 2 | 2014 | 168 | 0.130 |
Why?
|
| Perioperative Period | 1 | 2017 | 262 | 0.130 |
Why?
|
| Humans | 54 | 2024 | 758406 | 0.130 |
Why?
|
| Cadaver | 1 | 2019 | 1345 | 0.130 |
Why?
|
| Teaching Rounds | 1 | 2019 | 275 | 0.120 |
Why?
|
| Middle Aged | 31 | 2021 | 219568 | 0.120 |
Why?
|
| Urinary Catheterization | 2 | 2014 | 198 | 0.120 |
Why?
|
| Retrospective Studies | 18 | 2024 | 80168 | 0.120 |
Why?
|
| Hospital Costs | 2 | 2017 | 960 | 0.120 |
Why?
|
| Aged | 27 | 2021 | 168218 | 0.120 |
Why?
|
| Disease-Free Survival | 4 | 2012 | 6821 | 0.110 |
Why?
|
| Neoplasm Staging | 5 | 2023 | 11152 | 0.110 |
Why?
|
| Time Factors | 10 | 2015 | 39872 | 0.110 |
Why?
|
| Lymph Node Excision | 3 | 2022 | 1303 | 0.110 |
Why?
|
| Brachytherapy | 1 | 2021 | 1236 | 0.110 |
Why?
|
| Calculi | 1 | 2013 | 48 | 0.110 |
Why?
|
| Hematocrit | 1 | 2014 | 627 | 0.110 |
Why?
|
| Kidney | 3 | 2014 | 7016 | 0.110 |
Why?
|
| Educational Measurement | 1 | 2019 | 1248 | 0.100 |
Why?
|
| Databases, Factual | 3 | 2017 | 7980 | 0.100 |
Why?
|
| Salvage Therapy | 2 | 2022 | 1268 | 0.100 |
Why?
|
| Ureteroscopes | 1 | 2012 | 22 | 0.100 |
Why?
|
| Circumcision, Male | 1 | 2013 | 148 | 0.100 |
Why?
|
| Logistic Models | 4 | 2017 | 13276 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 4023 | 0.100 |
Why?
|
| Competency-Based Education | 1 | 2013 | 218 | 0.100 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2019 | 1008 | 0.100 |
Why?
|
| Electrosurgery | 1 | 2011 | 51 | 0.100 |
Why?
|
| Blood Coagulation Disorders | 1 | 2014 | 349 | 0.090 |
Why?
|
| Ergocalciferols | 1 | 2012 | 110 | 0.090 |
Why?
|
| Kidney Pelvis | 1 | 2011 | 188 | 0.090 |
Why?
|
| Lithotripsy | 1 | 2011 | 141 | 0.090 |
Why?
|
| Intraoperative Period | 1 | 2011 | 512 | 0.090 |
Why?
|
| Work Schedule Tolerance | 1 | 2014 | 551 | 0.090 |
Why?
|
| Gels | 1 | 2011 | 419 | 0.090 |
Why?
|
| Urologic Neoplasms | 1 | 2014 | 320 | 0.090 |
Why?
|
| Disease Progression | 3 | 2011 | 13468 | 0.090 |
Why?
|
| Computer-Assisted Instruction | 1 | 2013 | 362 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2014 | 2239 | 0.090 |
Why?
|
| Lacerations | 1 | 2012 | 148 | 0.090 |
Why?
|
| Sus scrofa | 1 | 2011 | 428 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2011 | 3217 | 0.090 |
Why?
|
| Urography | 1 | 2011 | 312 | 0.090 |
Why?
|
| Kidney Cortex | 1 | 2009 | 169 | 0.090 |
Why?
|
| Learning Curve | 1 | 2011 | 231 | 0.080 |
Why?
|
| Tissue Kallikreins | 1 | 2009 | 14 | 0.080 |
Why?
|
| Psychomotor Performance | 2 | 2014 | 1878 | 0.080 |
Why?
|
| Preoperative Period | 1 | 2011 | 553 | 0.080 |
Why?
|
| Organ Size | 2 | 2011 | 2252 | 0.080 |
Why?
|
| Endpoint Determination | 1 | 2011 | 590 | 0.080 |
Why?
|
| Electrodes | 1 | 2011 | 613 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2017 | 9650 | 0.080 |
Why?
|
| Intraoperative Complications | 1 | 2015 | 1184 | 0.080 |
Why?
|
| Regional Blood Flow | 1 | 2011 | 1486 | 0.080 |
Why?
|
| User-Computer Interface | 1 | 2014 | 1397 | 0.080 |
Why?
|
| Fatigue | 1 | 2014 | 1542 | 0.070 |
Why?
|
| Adult | 18 | 2022 | 219935 | 0.070 |
Why?
|
| Dyspnea | 1 | 2014 | 1344 | 0.070 |
Why?
|
| Stress, Mechanical | 1 | 2012 | 1664 | 0.070 |
Why?
|
| Aged, 80 and over | 11 | 2015 | 58683 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2022 | 3617 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 4048 | 0.070 |
Why?
|
| Prognosis | 6 | 2012 | 29557 | 0.070 |
Why?
|
| SEER Program | 1 | 2011 | 1530 | 0.070 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 1338 | 0.060 |
Why?
|
| Biopsy, Needle | 2 | 2007 | 1630 | 0.060 |
Why?
|
| United States | 8 | 2021 | 72136 | 0.060 |
Why?
|
| Ultrasonography, Doppler | 1 | 2007 | 463 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 12096 | 0.060 |
Why?
|
| Pain Measurement | 1 | 2014 | 3527 | 0.060 |
Why?
|
| Vitamins | 1 | 2012 | 1632 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 1721 | 0.050 |
Why?
|
| Female | 22 | 2022 | 390323 | 0.050 |
Why?
|
| Perioperative Care | 1 | 2011 | 1028 | 0.050 |
Why?
|
| Foreign Medical Graduates | 1 | 2024 | 77 | 0.050 |
Why?
|
| General Surgery | 1 | 2014 | 1677 | 0.050 |
Why?
|
| Nitrous Oxide | 1 | 2023 | 166 | 0.050 |
Why?
|
| Receptors, Androgen | 1 | 2009 | 1077 | 0.050 |
Why?
|
| Endosonography | 1 | 2007 | 607 | 0.050 |
Why?
|
| Administration, Intravesical | 1 | 2022 | 92 | 0.050 |
Why?
|
| Survival Rate | 4 | 2012 | 12721 | 0.050 |
Why?
|
| Ischemia | 1 | 2011 | 1863 | 0.050 |
Why?
|
| Education, Medical | 1 | 2014 | 1725 | 0.050 |
Why?
|
| Prevalence | 3 | 2022 | 15651 | 0.050 |
Why?
|
| Vitamin D Deficiency | 1 | 2012 | 1377 | 0.050 |
Why?
|
| Achievement | 1 | 2024 | 289 | 0.050 |
Why?
|
| Suprachiasmatic Nucleus | 1 | 2003 | 139 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2012 | 39059 | 0.050 |
Why?
|
| Forecasting | 1 | 2010 | 2923 | 0.050 |
Why?
|
| Venous Thromboembolism | 1 | 2014 | 1855 | 0.050 |
Why?
|
| Inguinal Canal | 1 | 2021 | 71 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2009 | 2472 | 0.050 |
Why?
|
| Curriculum | 1 | 2014 | 3717 | 0.050 |
Why?
|
| Lidocaine | 1 | 2023 | 537 | 0.040 |
Why?
|
| BCG Vaccine | 1 | 2022 | 371 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 3 | 2014 | 2154 | 0.040 |
Why?
|
| Prospective Studies | 6 | 2023 | 54137 | 0.040 |
Why?
|
| Incidence | 5 | 2021 | 21272 | 0.040 |
Why?
|
| Calcium | 1 | 2012 | 5721 | 0.040 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2003 | 699 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2011 | 5952 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2014 | 3765 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2022 | 1791 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2022 | 1038 | 0.040 |
Why?
|
| Muscles | 1 | 2022 | 1579 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2021 | 509 | 0.030 |
Why?
|
| Anesthetics, Local | 1 | 2023 | 1000 | 0.030 |
Why?
|
| Ureteral Calculi | 1 | 2017 | 116 | 0.030 |
Why?
|
| Tumor Burden | 2 | 2014 | 1893 | 0.030 |
Why?
|
| Predictive Value of Tests | 5 | 2011 | 15225 | 0.030 |
Why?
|
| Preoperative Care | 3 | 2011 | 2249 | 0.030 |
Why?
|
| Models, Biological | 1 | 2011 | 9460 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2022 | 1489 | 0.030 |
Why?
|
| Codeine | 1 | 2014 | 51 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 2850 | 0.030 |
Why?
|
| Urinary Bladder Calculi | 1 | 2013 | 12 | 0.030 |
Why?
|
| Area Under Curve | 2 | 2009 | 1632 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2022 | 1442 | 0.030 |
Why?
|
| Risk Factors | 7 | 2015 | 73809 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2022 | 3527 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 8506 | 0.030 |
Why?
|
| Cystitis | 1 | 2013 | 96 | 0.030 |
Why?
|
| Adolescent | 2 | 2011 | 87892 | 0.030 |
Why?
|
| Oxygen | 1 | 2023 | 4191 | 0.020 |
Why?
|
| Hematuria | 1 | 2013 | 233 | 0.020 |
Why?
|
| Constriction | 1 | 2011 | 172 | 0.020 |
Why?
|
| Swine | 2 | 2012 | 5892 | 0.020 |
Why?
|
| Young Adult | 3 | 2014 | 58808 | 0.020 |
Why?
|
| Cautery | 1 | 2011 | 71 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2003 | 2567 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2022 | 3485 | 0.020 |
Why?
|
| Motivation | 1 | 2021 | 1996 | 0.020 |
Why?
|
| Surgical Instruments | 1 | 2013 | 385 | 0.020 |
Why?
|
| Age Factors | 3 | 2015 | 18358 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 2821 | 0.020 |
Why?
|
| Acetaminophen | 1 | 2014 | 552 | 0.020 |
Why?
|
| Feedback | 1 | 2013 | 791 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2023 | 12262 | 0.020 |
Why?
|
| Sex Factors | 2 | 2015 | 10504 | 0.020 |
Why?
|
| Risk Assessment | 3 | 2021 | 23884 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 2011 | 588 | 0.020 |
Why?
|
| alpha-Amylases | 1 | 1989 | 39 | 0.020 |
Why?
|
| Hand | 1 | 2014 | 903 | 0.020 |
Why?
|
| Catheterization | 1 | 2014 | 1426 | 0.020 |
Why?
|
| Pain | 1 | 2023 | 5065 | 0.020 |
Why?
|
| Sesquiterpenes | 1 | 2009 | 176 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2009 | 250 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2011 | 8553 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 5786 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2014 | 2020 | 0.020 |
Why?
|
| Reference Values | 1 | 2015 | 4919 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2011 | 766 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2017 | 6354 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2022 | 36284 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2014 | 1063 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 1604 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2011 | 754 | 0.020 |
Why?
|
| Sodium | 1 | 2012 | 1588 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2013 | 1504 | 0.020 |
Why?
|
| Checklist | 1 | 2013 | 827 | 0.020 |
Why?
|
| Obesity | 1 | 2008 | 12870 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 1797 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 7985 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 2112 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2011 | 1471 | 0.020 |
Why?
|
| Critical Care | 1 | 2017 | 2692 | 0.010 |
Why?
|
| Saliva | 1 | 1989 | 820 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2009 | 1694 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2017 | 3245 | 0.010 |
Why?
|
| Autopsy | 1 | 2007 | 1003 | 0.010 |
Why?
|
| Hospitals | 1 | 2017 | 3887 | 0.010 |
Why?
|
| Length of Stay | 1 | 2017 | 6439 | 0.010 |
Why?
|
| Cohort Studies | 3 | 2011 | 41256 | 0.010 |
Why?
|
| Reoperation | 1 | 2013 | 4282 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2009 | 3602 | 0.010 |
Why?
|
| Child | 1 | 2011 | 79818 | 0.010 |
Why?
|
| Comorbidity | 1 | 2017 | 10495 | 0.010 |
Why?
|
| Medicare | 1 | 2021 | 6741 | 0.010 |
Why?
|
| Period Circadian Proteins | 1 | 2003 | 96 | 0.010 |
Why?
|
| Fasting | 1 | 1989 | 1599 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2008 | 2640 | 0.010 |
Why?
|
| Body Composition | 1 | 2011 | 2416 | 0.010 |
Why?
|
| Linear Models | 1 | 2012 | 5862 | 0.010 |
Why?
|
| Probability | 1 | 2007 | 2467 | 0.010 |
Why?
|
| Neurosecretory Systems | 1 | 2003 | 221 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2015 | 5272 | 0.010 |
Why?
|
| ROC Curve | 1 | 2009 | 3563 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2009 | 3574 | 0.010 |
Why?
|
| Animals | 5 | 2012 | 167768 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 4901 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 835 | 0.010 |
Why?
|
| Transgenes | 1 | 2003 | 1007 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 7818 | 0.010 |
Why?
|
| Vitamin D | 1 | 2012 | 3283 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 5779 | 0.010 |
Why?
|
| Hospitalization | 1 | 2017 | 10652 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 2057 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 20055 | 0.010 |
Why?
|
| Glucose | 1 | 1989 | 4336 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2003 | 1969 | 0.010 |
Why?
|
| Registries | 1 | 2011 | 8175 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2009 | 10416 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2013 | 26183 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 16886 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 14641 | 0.010 |
Why?
|
| Research Design | 1 | 2007 | 6157 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2003 | 3442 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2009 | 22029 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2008 | 12876 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 15785 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1989 | 5816 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 9518 | 0.010 |
Why?
|
| Mice | 2 | 2009 | 81101 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 11070 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 12759 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 13591 | 0.000 |
Why?
|
| Glucose Tolerance Test | 1 | 1989 | 1172 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 11892 | 0.000 |
Why?
|
| Neurons | 1 | 2003 | 9416 | 0.000 |
Why?
|
Concepts
(274)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(25)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_